Acurx Pharmaceuticals, Inc. financial data

Symbol
ACXP on Nasdaq
Location
Staten Island, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 179% %
Debt-to-equity 107% % 41%
Return On Equity -362% % 7.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2,085,363 shares -88%
Common Stock, Shares, Outstanding 1,800,299 shares -89%
Entity Public Float $30,600,000 USD 9.7%
Common Stock, Value, Issued $1,800 USD -89%
Weighted Average Number of Shares Outstanding, Basic 1,625,805 shares 99%
Weighted Average Number of Shares Outstanding, Diluted 1,625,805 shares 99%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $2,377,758 USD -64%
General and Administrative Expense $6,845,827 USD -31%
Operating Income (Loss) $2,028,701 USD 28%
Net Income (Loss) Attributable to Parent $9,170,053 USD 44%
Earnings Per Share, Basic 4 USD/shares 64%
Earnings Per Share, Diluted 4 USD/shares 64%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current $6,157,858 USD
Assets $6,105,211 USD
Employee-related Liabilities, Current $52,710 USD -79%
Liabilities, Current $2,468,175 USD -26%
Liabilities $2,468,175 USD -26%
Retained Earnings (Accumulated Deficit) $73,710,218 USD -14%
Stockholders' Equity Attributable to Parent $3,637,036 USD 37%
Liabilities and Equity $6,105,211 USD 2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,051,499 USD 33%
Net Cash Provided by (Used in) Financing Activities $2,988,673 USD -34%
Common Stock, Shares Authorized 250,000,000 shares 25%
Common Stock, Shares, Issued 1,800,299 shares -89%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $937,174 USD -35%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5,906,802 USD 2.5%
Deferred Tax Assets, Valuation Allowance $16,310,497 USD 37%
Deferred Tax Assets, Gross $16,310,497 USD 37%
Deferred Tax Assets, Operating Loss Carryforwards $8,017,189 USD 45%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $77,345,454 USD 15%
Preferred Stock, Shares Outstanding 0 shares